Table_1_Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets.XLSX

• Main Authors: Dana Mitchell, Sreenivasulu Chintala, Kaleigh Fetcko, Mario Henriquez, Brij N. Tewari, Atique Ahmed, R. Timothy Bentley, Mahua Dey
• Format: Dataset
• Language: unknown
• Published: 2019
• Subjects: Cancer; Cancer Cell Biology; Cancer Diagnosis; Cancer Genetics; Cancer Therapy (excl. Chemotherapy and Radiation Therapy); Chemotherapy; Haematological Tumours; Molecular Targets; Radiation Therapy; Solid Tumours; Oncology and Carcinogenesis not elsewhere classified; canine glioma; glioblastoma; molecular therapeutic targets; malignant glioma; anaplastic oligodendroglioma; Canis lupus
• Online Access: https://doi.org/10.3389/fonc.2019.00780.s002; https://figshare.com/articles/Table_1_Common_Molecular_Alterations_in_Canine_Oligodendroglioma_and_Human_Malignant_Gliomas_and_Potential_Novel_Therapeutic_Targets_XLSX/9609959

Spontaneous canine (Canis lupus) oligodendroglioma (ODG) holds tremendous potential as an immunocompetent large animal model of human malignant gliomas (MG). However, the feasibility of utilizing this model in pre-clinical studies depends on a thorough understanding of the similarities and differences of the molecular pathways associated with gliomas between the two species. We have previously shown that canine ODG has an immune landscape and expression pattern of commonly described oncogenes similar to that of human MG. In the current study, we performed a comprehensive analysis of canine ODG RNAseq data from 4 dogs with ODG and 2 normal controls to identify highly dysregulated genes in canine tumors. We then evaluated the expression of these genes in human MG using Xena Browser, a publicly available database. STRING-database inquiry was used in order to determine the suggested protein associations of these differentially expressed genes as well as the dysregulated pathways commonly enriched by the protein products of these genes in both canine ODG and human MG. Our results revealed that 3,712 (23%) of the 15,895 differentially expressed genes demonstrated significant up- or downregulation (log2-fold change > 2.0). Of the 3,712 altered genes, ~50% were upregulated (n = 1858) and ~50% were downregulated (n = 1854). Most of these genes were also found to have altered expression in human MG. Protein association and pathway analysis revealed common pathways enriched by members of the up- and downregulated gene categories in both species. In summary, we demonstrate that a similar pattern of gene dysregulation characterizes both human MG and canine ODG and provide additional support for the use of the canine model in order to therapeutically target these common genes. The results of such therapeutic targeting in the canine model can serve to more accurately predict the efficacy of anti-glioma therapies in human patients.